Cannabidiol for epilepsy expected to be available within 6 weeks: industry news round-up

Written by Sharon Salt, Editor

This week’s industry news round-up reveals the latest updates including a new medicine for migraine, a rescheduling of cannabidiol for epilepsy and a successful Phase III trial for neuromyelitis optica spectrum disorder. Find out more about our selection of the highlights below. Our selection of the highlights includes: Emgality™ receives marketing authorization for the prevention of migraine Alexion reveals positive results for Soliris® in patients with neuromyelitis optica spectrum disorder GW Pharmaceuticals announces DEA reschedule of Epidiolex® for epilepsy Emgality™ receives marketing authorization for the prevention of migraine The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended...

To view the full article, please register now for access

It's completely free